Investigational CRT-402 for treatment-resistant autoimmune disease
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.
This trial tests an investigational treatment called CRT-402 for people with certain autoimmune diseases that have not responded to standard therapy. The goal is to see if it can help control the disease and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have one of these active autoimmune diseases that has not improved with standard treatment: systemic lupus erythematosus, systemic sclerosis, or idiopathic inflammatory myopathy.
- Your major organs, like kidneys, liver, heart, and lungs, must be working well enough, as determined by the study doctors.
- If you can have children, you must agree to use birth control during the trial and for a period after the last dose.
- Females who could become pregnant must have a negative pregnancy test before starting treatment.
- You must be willing to attend all study visits and follow all trial instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This trial tests a special type of cell therapy (CAR-T cells) to see if it can help treat autoimmune diseases like lupus or scleroderma. If you qualify, you might get a chance to try this new approach that could help your immune system stop attacking your own body.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.